ANI Pharmaceuticals (NASDAQ:ANIP) Director Sells $320,819.75 in Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Director Patrick Walsh sold 3,973 shares of the firm’s stock in a transaction on Monday, May 11th. The stock was sold at an average price of $80.75, for a total transaction of $320,819.75. Following the completion of the sale, the director owned 48,432 shares of the company’s stock, valued at $3,910,884. This trade represents a 7.58% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

ANI Pharmaceuticals Stock Performance

Shares of ANIP opened at $78.01 on Friday. The company has a 50-day simple moving average of $77.29 and a 200-day simple moving average of $80.48. The company has a quick ratio of 2.52, a current ratio of 3.12 and a debt-to-equity ratio of 1.06. The company has a market capitalization of $1.77 billion, a PE ratio of 19.75 and a beta of 0.46. ANI Pharmaceuticals, Inc. has a 52-week low of $56.71 and a 52-week high of $99.50.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings results on Friday, May 8th. The specialty pharmaceutical company reported $2.05 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.28 by $0.77. The business had revenue of $237.46 million during the quarter, compared to the consensus estimate of $207.63 million. ANI Pharmaceuticals had a net margin of 9.98% and a return on equity of 27.51%. The business’s revenue was up 20.5% compared to the same quarter last year. During the same quarter last year, the firm posted $1.70 EPS. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. Equities research analysts predict that ANI Pharmaceuticals, Inc. will post 7.73 earnings per share for the current fiscal year.

Analyst Ratings Changes

ANIP has been the subject of a number of recent research reports. Wall Street Zen upgraded shares of ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 9th. Zacks Research raised shares of ANI Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, April 15th. Finally, Guggenheim boosted their target price on shares of ANI Pharmaceuticals from $115.00 to $124.00 and gave the stock a “buy” rating in a research report on Friday, January 16th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, ANI Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $107.33.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. Arrowstreet Capital Limited Partnership bought a new stake in shares of ANI Pharmaceuticals in the third quarter worth $32,992,000. Balyasny Asset Management L.P. increased its stake in shares of ANI Pharmaceuticals by 2,785.7% in the third quarter. Balyasny Asset Management L.P. now owns 286,149 shares of the specialty pharmaceutical company’s stock worth $26,211,000 after buying an additional 276,233 shares during the last quarter. Divisadero Street Capital Management LP bought a new stake in shares of ANI Pharmaceuticals in the third quarter worth $21,454,000. Rubric Capital Management LP increased its stake in shares of ANI Pharmaceuticals by 354.7% in the second quarter. Rubric Capital Management LP now owns 257,669 shares of the specialty pharmaceutical company’s stock worth $16,813,000 after buying an additional 200,998 shares during the last quarter. Finally, UBS Group AG increased its stake in shares of ANI Pharmaceuticals by 45.8% in the third quarter. UBS Group AG now owns 589,874 shares of the specialty pharmaceutical company’s stock worth $54,032,000 after buying an additional 185,172 shares during the last quarter. 76.05% of the stock is owned by institutional investors and hedge funds.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.